Evaluation of the possible protective effect of Curmeric on the clinical evolution of patients in the post-acute and chronic period of Chikungunya disease

Evaluation of the possible protective effect of Curmeric on the clinical evolution of patients hospitalized at the IPK and in the post-acute and chronic period of Chikungunya disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000466

Enrollment

150

Registered

2025-12-04

Start date

2025-12-08

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute, post-acute and chronic phases of chikungunya

Interventions

Group I Curmeric (Experimental): Patients with no history of Curmeric use: 4 mL (1 teaspoon) three times a day after meals. Patients with a history of Curmeric use for more than 1 month: 4 mL (1 teasp

Eligibility

Sex/Gender

All

Age

19 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 19 and over admitted to the IPK with a clinical diagnosis of Chikungunya disease. 2. Patients who provide their informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of allergy to turmeric or its derivatives 2. Pregnant or breastfeeding women 3. Patients with bleeding disorders or blood dyscrasias 4. Diseases of the biliary tract, chronic liver disease, hematological malignancies, and chronic rheumatological conditions 5. Terminal illness

Design outcomes

Primary

Measure	Time frame
Symptoms (Type of symptom (Joint pain, Visible swelling in joints, Redness and warmth of joints, Muscle pain, Neuralgia with pain along the limb, Headaches, Nausea, General malaise, Fatigue, Rash, Bleeding, Diarrhea, Conjunctivitis); Symptom intensity (Measurement according to the VAS visual analog scale representing pain intensity where: a value less than 4 means mild or mild-moderate pain, a value between 4 and 6 implies the presence of moderate-severe pain, and a value greater than 6 implies the presence of very intense pain). Measurement time: At baseline, day 30, day 60 and day 90	—

Measure

Time frame

Symptoms (Type of symptom (Joint pain, Visible swelling in joints, Redness and warmth of joints, Muscle pain, Neuralgia with pain along the limb, Headaches, Nausea, General malaise, Fatigue, Rash, Bleeding, Diarrhea, Conjunctivitis); Symptom intensity (Measurement according to the VAS visual analog scale representing pain intensity where: a value less than 4 means mild or mild-moderate pain, a value between 4 and 6 implies the presence of moderate-severe pain, and a value greater than 6 implies the presence of very intense pain). Measurement time: At baseline, day 30, day 60 and day 90

—

Secondary

Measure	Time frame
Adverse Events-AE (Occurrence of any AE (Yes, No); Description of the AE (Name of the adverse event/treatment); Duration of the AE (start and stop dates of the event) Intensity of the AE (mild, moderate, and severe); Severity (yes/no) yes: Patient death, Life-threatening condition, Hospitalization or prolongation of an existing hospitalization, Resulting in significant or persistent disability/impairment, Resulting in birth defect or congenital anomaly, Other events that may require any medical or surgical intervention to prevent any of the aforementioned conditions.) no: Not applicable. Measurement time: day 30, day 60, and day 90). Measurement time: day 30, day 60, and day 90	—

Measure

Time frame

Adverse Events-AE (Occurrence of any AE (Yes, No); Description of the AE (Name of the adverse event/treatment); Duration of the AE (start and stop dates of the event) Intensity of the AE (mild, moderate, and severe); Severity (yes/no) yes: Patient death, Life-threatening condition, Hospitalization or prolongation of an existing hospitalization, Resulting in significant or persistent disability/impairment, Resulting in birth defect or congenital anomaly, Other events that may require any medical or surgical intervention to prevent any of the aforementioned conditions.) no: Not applicable. Measurement time: day 30, day 60, and day 90). Measurement time: day 30, day 60, and day 90

—

Countries

Cuba

Contacts

Public ContactBeatriz Sierra Vazquez

“Pedro Kouri” Institute of Tropical Medicine (IPK)

siebet@ipk.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 25, 2026